Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects With Moderate-to-severe Atopic Dermatitis

Next Previous
Trial Profile

A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects With Moderate-to-severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tozorakimab (Primary)
  • Indications Atopic dermatitis; Eczema
  • Focus Therapeutic Use
  • Acronyms FRONTIER-AD
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 01 Jun 2025 Primary endpoint (The severity of the signs of eczema and the extent affected as graded by Eczema Area and Severity Index, including change from baseline) has not been met.
  • 01 Jun 2025 Results published in the Journal of the European Academy of Dermatology and Venereology
  • 11 Oct 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top